



NEW YORK PHARMA FORUM

**THURSDAY, JANUARY 17, 2013**

---

**TOPIC:** TransCelerate BioPharma Inc.: New Collaborative Effort of Ten Industry Companies to Accelerate Drug Development

**SPEAKER:** Garry Neil, MD  
Chairman, TransCelerate BioPharma Inc.

According to an article in March in [Nature Reviews Drug Discovery](#), the approval rate of new drugs when measured against the amount spent annually on R&D has fallen by 50 percent roughly every nine years since 1950. To fight this trend, ten biopharmaceutical companies have joined together to form a non-profit organization to accelerate new drug development. The ten companies (Abbott, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly and Company, GlaxoSmithKline, Johnson & Johnson, Pfizer, Genentech and Sanofi) have just launched this organization, named TransCelerate BioPharma Inc. The launch announcement stated that membership in TransCelerate is open to all biopharma companies.

The organization's board of directors will include the heads of R&D of all ten founding companies. Clinical study execution will be TransCelerate's initial area of focus. The organization will undertake five projects: development of a shared user interface for investigator site portals, mutual recognition of study site qualification and training, development of risk-based site monitoring approach and standards, development of clinical data standards, and establishment of a comparator drug supply model.

Our speaker, the acting CEO of TransCelerate, Garry Neil, MD, will discuss how this new organization came about and how it will work across both corporate and national boundaries to share research and find solutions to accelerate drug development. Dr. Neil, who is a partner at Apple Tree Partners, has many years of experience in science, medicine and pharmaceutical development. He is former Corporate Vice President, Science & Technology, Johnson & Johnson, and, prior to that, he was Group President, Johnson & Johnson Pharmaceutical Research and Development. Dr. Neil also has held academic posts at various institutions and has written more than 50 articles and book chapters.